
Iktos
Iktos
Claim
We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.We are Iktos. A start-up company specializing in the development of proprietary artificial intellige Show More
Alpha Score
$ 69.15 M
Alpha Score
60.6
Predictions
Overview
Team
Financials
- Partnerships
Relationships
Locations
Competitors
Comparison
News
Product
Regulatory
Clinical
Patent
Publications
Notes
0and0